摘要
目的:评价碳酸锂联合帕罗西汀治疗抑郁症的疗效及安全性。方法:105例符合中国精神疾病诊断分类第3版(CC- MD-3)抑郁发作标准的抑郁症病人分为2组,分别给予碳酸锂联合帕罗西汀治疗(治疗组)和单用帕罗西汀治疗(对照组),疗程均为10周。根据汉密尔顿抑郁量表(HAMD)减分率评定疗效,用副反应量表(TESS)评定用药的安全性,在治疗前和治疗后的1,2,4,6,8,10周末分别对2组进行检查评定。结果:治疗组总有效率为76.5%,对照组总有效率为50.0%。2组间,疗效比较差异有统计学意义(P<0.01),不良反应的发生率无统计学差异(P>0.05),治疗组的转躁率低于对照组。结论:碳酸锂联合帕罗西汀治疗抑郁症可增强疗效,起效快,安全性好。
Objective： To assess the therapeutic effects and safety of lithium crbonate combined with paroxetine on treatment of depression. Method ： One hundred and five patients with depression were divided into two groups, the treatment group （ 53 patients） and the control group （52 patients）. The patients of the treatment group were given lithium carbonate combined with paroxetine and the control group were given paroxetine only. The duration of treatment in both groups were 10 wk. The clinical therapeutic effects were assessed with the Hamilton Depressive Scale（HAMD） and the safety of drugs were evaluated with the Treatment Emergent Symptom Scale （TESS）. HAMD and TESS of two groups were assessed before and at 1,2,4,6,8,10 wk after treatment. Result： The total rates of the therapeutic effects in patients of the treatment group and control group were 76.5% and 50.0% respectively with statistical difference （P 〈 0.01 ）. There were no statistical difference rates of TESS between two groups （ P 〉 0.05 ）. It showed much lower incidence from depression shifted to mania episode in the treatment group. Conclusion： Lithium carbonate combined with paroxotine is more effectiveness and safty in the treatment of patients with depression.
出处
《中国药师》
CAS
2008年第11期1347-1349,共3页
China Pharmacist
关键词
碳酸锂
帕罗西汀
抑郁症
Lithium carbonate
Paroxetine
Depression
